All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 19 points (-0.1%) at 17,641 as of Friday, May 6, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,494 issues advancing vs. 1,386 declining with 173 unchanged.

The Health Services industry currently sits down 1.0% versus the S&P 500, which is down 0.3%. A company within the industry that increased today was PerkinElmer ( PKI), up 6.2%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 2.6%, Humana ( HUM), down 2.3%, Mettler-Toledo International ( MTD), down 1.9%, Abbott Laboratories ( ABT), down 1.6% and Baxter International ( BAX), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Dentsply Sirona ( XRAY) is one of the companies pushing the Health Services industry higher today. As of noon trading, Dentsply Sirona is up $1.00 (1.6%) to $61.49 on average volume. Thus far, 1.4 million shares of Dentsply Sirona exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $60.60-$62.00 after having opened the day at $61.94 as compared to the previous trading day's close of $60.49.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the United States and internationally. Dentsply Sirona has a market cap of $8.4 billion and is part of the health care sector. Shares are down 0.6% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts who rate Dentsply Sirona a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Dentsply Sirona as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Dentsply Sirona Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Edwards Lifesciences ( EW) is up $0.56 (0.5%) to $104.93 on light volume. Thus far, 603,750 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $103.94-$105.13 after having opened the day at $104.12 as compared to the previous trading day's close of $104.37.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $22.0 billion and is part of the health care sector. Shares are up 32.1% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Edwards Lifesciences Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $1.38 (0.9%) to $146.52 on light volume. Thus far, 476,324 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $144.86-$146.77 after having opened the day at $144.99 as compared to the previous trading day's close of $145.14.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. Thermo Fisher Scientific has a market cap of $57.3 billion and is part of the health care sector. Shares are up 2.3% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Thermo Fisher Scientific a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).